DUBLIN--(BUSINESS WIRE)--The "Orphan Drug Access and Pricing in Emerging Markets" report has been added to ResearchAndMarkets.com's offering.
This analysis covers the four major emerging regions of the Middle East and Africa, Latin America, Eastern Europe, and Asia-Pacific. Within these regions, relatively wealthier markets with a proven marketplace for orphan medicines have been prioritized.
The topic focus is on rare-disease policy, access, and pricing, as well as the stakeholder landscape for low-prevalence disorders and orphan drugs.
For the purposes of this analysis, local definitions for rare disease were used where available, as well as conventional definitions of both ultra-orphan disorders and rare tumor types.
The insights in this analysis are aimed at a general audience within the market access and pricing field, with a limited amount of disease-specific information. In this review, key market access customers for rare diseases in 20 emerging markets have been analyzed, as well as pricing and funding pathways where these specifically relate to orphan drugs.
Key Topics Covered:
Budget limitations are a major hurdle but opportunities still exist for some rare diseases
Each market will require customized access strategy to maximize chance of success
Lack of diagnosis and treatment infrastructure, coupled with payer rigidity present key access challenges
Gulf region presents the most lucrative opportunity, with well-funded niches in other regions
KEY FEATURES OF EMERGING ORPHAN DRUG MARKETS
Orphan drugs and emerging markets are industry growth engines
The orphan drug business model requires local adaptation
RARE DISEASE POLICY AND CAPABILITY
Prevalence-based definitions of rare diseases are a critical step
Legal frameworks are often incoherent
Challenges in diagnostic and treatment infrastructure
Policy does not guarantee access
PRICING, REIMBURSEMENT, AND MARKET ACCESS
Payers' rigidity is the key market access challenge
Exceptional access mechanisms exist in some leading emerging markets
Payers misuse international price referencing for orphan drugs
Registries are evolving in emerging markets
PRIORITY EMERGING ORPHAN DRUG MARKETS
The Gulf states are the stand-out opportunity
Only the Middle East matches prevalence with funding
Heterogeneity drives specific local needs
Emerging markets are not ready for new technology
Manufacturers should match resources to access
For more information about this report visit https://www.researchandmarkets.com/research/kvvhtz/global_orphan?w=4